Figure 4 - Management of asthma patients during COVID-19 pandemic
Assuring patients safety can be provided by prevention of infection with SARS-CoV2 and appropriate control of asthma. In addition to personal protection by using a mask, hand sanitizer, washing hands and socially distancing, the control of asthma symptoms is essential. The decision of sustaining or postponing the therapy of asthma (severe) patients must be taken multidisciplinary and based on individual circumstances. The usage of ICS and other asthma controllers should be continued. Several EAACI position papers have been published on patient management during the COVID-19 pandemics that should be referred in specific conditions, such as biological usage, allergen immunotherapy, drug hypersensitivity, venom immunotherapy, ophtalmology and asthma. EAACI, European Academy of Allergy and Clinical Immunology; COVID, Coronavirus Disease 2019; Inhale corticosteroids, ICS.